Ocular Therapeutix™ to Participate in Clinical Trials at the Summit 2026
Rhea-AI Summary
Ocular Therapeutix (NASDAQ:OCUL) will participate in Clinical Trials at the Summit 2026 in Las Vegas on June 12-13, 2026. Company leaders and external experts will join fireside chats and panels focused on OTX-TKI and retinal diseases.
Multiple sessions will cover efficacy, safety, and program updates.
Positive
- None.
Negative
- None.
News Market Reaction – OCUL
In the Jun 4 session, OCUL gained 5.39%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.1% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 02 | Investor Day announcement | Positive | -6.9% | Announced June 17, 2026 Investor Day with pipeline and NDA plan updates. |
| May 15 | Inducement grants | Neutral | -3.6% | Reported inducement equity awards to new HR leadership under stock plan. |
| May 08 | Inducement grants | Neutral | -3.8% | Granted stock options and RSUs to newly hired non‑executive employees. |
| May 05 | Earnings and pipeline | Positive | -0.6% | Reported Q1 2026, positive SOL‑1 Phase 3 data and strong cash runway. |
| Apr 29 | Clinical trial update | Positive | -1.2% | Announced first patient enrolled in SOL‑X long‑term extension for AXPAXLI. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent OCUL news, including positive clinical and corporate updates, has often been followed by negative next‑day price reactions, indicating a pattern of selling into news.
Over the last few months, OCUL has reported several milestones: enrollment in the SOL‑X long‑term extension trial, positive Phase 3 SOL‑1 superiority results with a p‑value of 0.0006, and strong cash of $666.7M as of Mar 31, 2026. It also announced upcoming Investor Day and routine inducement grants. Despite these constructive updates, the stock saw negative 24‑hour reactions after most events, providing context for today’s neutral conference‑participation headline against a still‑subdued share price.
Key Terms
phase 3 medical
neovascular amd medical
nonproliferative diabetic retinopathy medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., June 04, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation at Clinical Trials at the Summit 2026, taking place on June 12-13, 2026, in Las Vegas, Nevada.
Clinical Trials at the Summit (CTS) 2026 Presentation Details:
- Fireside Chat with Wiley Chambers, MD
Fireside Date/Time: Friday, June 12, 2026, 8:05 – 8:30 PM PT
Moderators: Jeffrey S. Heier, MD, Chief Scientific Officer; Peter K. Kaiser, MD, Chief Development Officer
- Presentation Title: OTX-TKI: Overview of Science
Session: Clinical Trials Addressing nAMD, DME, and DR
Presentation Date/Time: Saturday, June 13, 2026,10:41 – 10:45 AM PT
Presenter: Peter K. Kaiser, MD, Chief Development Officer
- Presentation Title: SOL-1 Phase 3 Superiority Trial: Efficacy Outcomes with OTX-TKI in Neovascular AMD
Session: Clinical Trials Addressing nAMD, DME, and DR
Presentation Date/Time: Saturday, June 13, 2026,10:53 – 10:57 AM PT
Presenter: Mark R. Barakat, MD
- Presentation Title: Safety and Tolerability Profile of OTX-TKI in Neovascular AMD
Session: Clinical Trials Addressing nAMD, DME, and DR
Presentation Date/Time: Saturday, June 13, 2026, 10:57 – 11:01 AM PT
Presenter: Darius M. Moshfeghi, MD
- Presentation Title: HELIOS Program Update on OTX-TKI in Nonproliferative Diabetic Retinopathy
Session: Clinical Trials Addressing nAMD, DME, and DR
Presentation Date/Time: Saturday, June 13, 2026, 11:05 – 11:09 AM PT
Presenter: Patricio G. Schlottmann, MD
- Fireside Chat: From Global KOL to CEO: The Journey of Innovation, Leadership, and Patient Impact
Fireside Date/Time: Saturday, June 13, 2026, 11:22 – 11:42 AM PT
Fireside Moderator: Arshad M. Khanani, MD, MA, FASRS
Panelist: Pravin U. Dugel, MD, Executive Chairman, President and CEO
- Panel Title: From Innovation to Approval: Bringing Novel Treatments to Market
Panel Date/Time: Saturday, June 13, 2026, 1:43 – 2:03 PM PT
Panel Moderator: Pravin U. Dugel, MD, Executive Chairman, President and CEO
Exact presentation times may be subject to change.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is an integrated biopharmaceutical company committed to redefining the retina experience. AXPAXLI™ (also known as OTX-TKI), Ocular’s investigational product candidate for retinal disease, is an axitinib intravitreal hydrogel based on its ELUTYX™ proprietary bioresorbable hydrogel-based formulation technology. AXPAXLI is currently in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic retinal disease, including non-proliferative diabetic retinopathy (NPDR).
Ocular’s pipeline also leverages the ELUTYX technology in its commercial product DEXTENZA®, an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older, and in its investigational product candidate OTX-TIC, which is a travoprost intracameral hydrogel that has completed a Phase 2 clinical trial for the treatment of open-angle glaucoma or ocular hypertension. Ocular is currently evaluating next steps for the OTX-TIC program.
Follow the Company on its website, LinkedIn, or X.
DEXTENZA® is a registered trademark of Ocular Therapeutix, Inc. The Ocular Therapeutix logo, AXPAXLI™, ELUTYX™, and Ocular Therapeutix™ are trademarks of Ocular Therapeutix, Inc.
Investors & Media
Ocular Therapeutix, Inc.
Bill Slattery
Vice President, Investor Relations
bslattery@ocutx.com
